Barclays Maintains Overweight on BeOne Medicines, Lowers Price Target to $403
Benzinga • July 14, 2026
Create a free account to read news articles and stay informed on market developments.
Already have an account? Sign in
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
